http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Ironwood Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference
-
Ironwood Pharmaceuticals to Present at Wells Fargo 2016 Healthcare Conference
-
Ironwood Pharmaceuticals Provides Second Quarter 2016 Investor Update
-
Ironwood Pharmaceuticals to Host Second Quarter 2016 Investor Update Call
-
Allergan (AGN), Ironwood Pharma's (IRWD) Linaclotide sNDA Accepted for Review by U.S. FDA
-
Ironwood and Allergan Announce Supplemental New Drug Application for 72 mcg Linaclotide in Chronic Idiopathic Constipation Has Been Accepted for FDA Review
-
Ironwood Pharmaceuticals to Present at Jefferies 2016 Healthcare Conference
-
Ironwood Pharma (IRWD) Announces Closure of Lesinurad Transaction with AstraZeneca (AZN)
-
Ironwood Pharmaceuticals Closes U.S. Transaction with AstraZeneca for Lesinurad
-
Ironwood Pharmaceuticals to Present at Goldman Sachs 37th Annual Global Healthcare Conference
-
Ironwood Pharmaceuticals to Present at 2016 UBS Global Healthcare Conference
-
Ironwood Pharmaceuticals to Present Linaclotide Data at Digestive Disease Week® 2016
-
Ironwood Pharmaceuticals Provides First Quarter 2016 Investor Update
-
Ironwood Pharmaceuticals to Present at Bank of America Merrill Lynch 2016 Health Care Conference
-
IMPORTANT SHAREHOLDER NOTICE: Goldberg Law PC Announces an Investigation of Claims against Ironwood Pharmaceuticals, Inc. and Advises Investors with Losses to Contact the Firm
-
Ironwood Pharmaceuticals Enters into U.S. Licensing Agreement with AstraZeneca for Lesinurad
-
Ironwood Pharmaceuticals to Host First Quarter 2016 Investor Update Call
-
Ironwood Pharma (IRWD) Adds New Board Member
-
Ironwood Pharmaceuticals Appoints Andrew Dreyfus to Board of Directors
-
Pre-Open Stock Movers 04/05: (VRX) (MRVL) (ICPT) Higher; (PSUN) (AGN) (NATI) Lower (more...)
-
Ironwood Pharma (IRWD) to Discontinue Development of IW-9179 for Gastroparesis
-
Ironwood Pharmaceuticals Reports Top-Line Data from Exploratory Phase IIa Study of IW-9179 in Diabetic Gastroparesis
-
Ironwood Pharmaceuticals to Present Clinical and Preclinical Data on sGC Stimulators at Upcoming Scientific Conferences
-
Ironwood Pharma (IRWD) Commences IW-3718 Phase 2b in Refractory Gastroesophageal Reflux
-
Ironwood Pharmaceuticals Initiates Phase IIb Clinical Trial of IW-3718 in Refractory Gastroesophageal Reflux Disease
-
Ironwood Pharmaceuticals to Present at Barclays Global Healthcare Conference
-
Ironwood Pharmaceuticals to Present at Cowen and Company 36th Annual Health Care Conference
-
Ironwood Pharma (IRWD) Partner Files NDA in Japan for Linaclotide to Treat Adults with IBS-C
-
Ironwood Pharmaceuticals Announces Filing by Astellas of New Drug Application in Japan with Linaclotide for the Treatment of Adults with IBS-C
-
Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2015 Investor Update
-
Ironwood Pharma (IRWD) to Initiate Phase Ib Study of IW-1701 Following Positive Top-Line Phase Ia Data
-
Ironwood Pharmaceuticals Progresses Vascular and Fibrotic Disease Platform with Positive Top-Line Phase Ia Data on Soluble Guanylate Cyclase Stimulator IW-1701
-
Ironwood Pharmaceuticals to Present at 2016 RBC Capital Markets Global Healthcare Conference
-
Ironwood Pharmaceuticals to Host Fourth Quarter and Full-Year 2015 Investor Update Call
-
Ironwood Pharma (IRWD) Highlights 2015 Accomplishments; Offers Five-Year Operating Goals
-
Ironwood Pharmaceuticals Details Strategy to Build Top-Performing Commercial Biotechnology Company
-
Ironwood Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
-
Astellas and Ironwood Report Positive Top-Line Data from Phase III IBS-C Trial Conducted in Japan
-
Ironwood Reports Positive Top-Line Data from Phase II Trial of Linaclotide in Adult Patients With Opioid-Induced Constipation
-
Ironwood Pharmaceuticals to Present at Credit Suisse 24th Annual Healthcare Conference
-
Ironwood Pharmaceuticals Provides Third Quarter 2015 Investor Update
-
Ironwood Pharmaceuticals Initiates Clinical Studies of Soluble Guanylate Cyclase Stimulators IW-1973 and IW-1701
-
Ironwood and Allergan Initiate Phase IIb Clinical Trial of Linaclotide Colonic Release in Adults with Irritable Bowel Syndrome with Constipation
-
Allergan Acquires Rights To Ironwood's CONSTELLA® (Linaclotide) From Almirall In More Than 40 Countries
-
Ironwood Highlights Refractory GERD and Constipation Research at the American College of Gastroenterology 2015 Annual Scientific Meeting
-
Ironwood Pharmaceuticals to Host Third Quarter 2015 Investor Update Call
-
Ironwood Reports Positive Top-Line Results from Phase III Trial of 72 mcg Linaclotide in Adults with Chronic Idiopathic Constipation
-
Ironwood Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference
-
Ironwood Pharmaceuticals Provides Second Quarter 2015 Investor Update
-
Ironwood and Allergan Enter Agreement to Co-Promote VIBERZI for Irritable Bowel Syndrome with Diarrhea (IBS-D) in the U.S.

